SCHEMBL23938229

SCHEMBL23938229

Cc1ncnc2scc(N)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 5/20 0.41
LCK P06239 5/20 0.41
MAP4K2 Q12851 5/20 0.41
MET P08581 4/20 0.41
KDR P35968 4/20 0.41
CLK2 P49760 4/20 0.41
RPS6KA3 P51812 4/20 0.41
CLK4 Q9HAZ1 4/20 0.41
CSF1R P07333 4/20 0.41
GSK3A P49840 3/20 0.41
TAOK1 Q7L7X3 3/20 0.41
ABL1 P00519 3/20 0.41
NTRK1 P04629 3/20 0.41
RET P07949 3/20 0.41
FGFR1 P11362 3/20 0.41
GSK3B P49841 3/20 0.41
CDK5 Q00535 3/20 0.41
ROCK1 Q13464 3/20 0.41
DYRK1A Q13627 3/20 0.41
NTRK2 Q16620 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL422306 0.79 MRGPRX1 (0.47) MAP4K4LCKMAP4K2METKDR
SCHEMBL23599237 0.76 MAP4K4 (0.50) MAP4K4LCKMAP4K2METKDR
SCHEMBL23599233 0.76 MRGPRX1 (0.45) MAP4K4LCKMAP4K2METKDR
SCHEMBL1901292 0.72 MAP4K4 (0.53) MAP4K4LCKMAP4K2METKDR
SCHEMBL13747077 0.72 SMN1; SMN2 (0.41) MAP4K4LCKMAP4K2METKDR
SCHEMBL16801668 0.69 FGFR1 (0.67) MAP4K4LCKMAP4K2METKDR
SCHEMBL13763179 0.68 CYP17A1 (0.40) MAP4K4LCKMAP4K2METKDR
SCHEMBL16281238 0.67 KDM4E (0.56) L3MBTL1ALDH1A1LMNAKDM4ETSHR
SCHEMBL13527777 0.67 SMN1; SMN2 (0.68) FGFR1L3MBTL1ALDH1A1LMNAKDM4E
SCHEMBL15743285 0.65 MAP4K4 (0.50) MAP4K4LCKMAP4K2METKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO EARLY DISCOVERY, INC. 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS USP28, USP25, USP24 MAP4K4 1430/4885LCK 3439/4885MAP4K2 1173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.